Prosaptide prevents paclitaxel neurotoxicity

Area of Science:

• Neuroscience
• Pharmacology
• Oncology

Background:

• Paclitaxel (Taxol) is a chemotherapy drug that can cause sensory neuropathy.
• Neurotrophic factors, like prosaposin and its derived prosaptides, show potential in preventing or reversing chemotherapy-induced nerve damage.
• Prosaptides, particularly TX14(A), have demonstrated neurotrophic activity.

Purpose of the Study:

• To investigate the efficacy of prosaptides TX14(A) and 769P in preventing paclitaxel-induced neurotoxicity.
• To assess the impact of prosaptides on paclitaxel's anti-tumor activity in vitro.

Main Methods:

• In vitro: PC12 and Schwann cells were treated with paclitaxel and TX14(A) to assess cell viability.
• In vivo: Adult rats were administered paclitaxel and prosaptides (TX14(A) or 769P) to evaluate neurotoxicity (thermal hypoalgesia) and systemic effects.
• Paclitaxel cytotoxicity on breast cancer cells was also evaluated in vitro.

Main Results:

• TX14(A) protected PC12 cells from paclitaxel-induced cell death but not Schwann cells.
• In rats, paclitaxel induced thermal hypoalgesia, which was prevented by co-administration with prosaptides.
• Prosaptides did not interfere with paclitaxel's cytotoxicity against breast cancer cells in vitro.

Conclusions:

• Prosaptides show promise in preventing paclitaxel-induced peripheral neuropathy.
• The neuroprotective effect of prosaptides does not compromise paclitaxel's efficacy against cancer cells.
• Prosaptides represent a potential therapeutic strategy to mitigate chemotherapy-induced neurotoxicity.